coronary artery atherosclerosis is, multifactorial, complex disease locally, and a major cause of death in the United States. complex interaction between transport biochemical and biomechanical forces affecting the growth of the disease.
Wall shear stress (WSS) influence coronary artery atherosclerosis by inducing endothelial cell mechanotransduction and by controlling the near-wall transport processes involved in atherosclerosis. Each process is controlled by a different WSS and because it has complicated the interpretation of WSS in atherosclerosis. In this paper, we present a comprehensive theory for WSS in atherosclerosis.
First, a brief review of mechanotransduction shear stress-mediated atherosclerosis is presented. Next, a special subject of computational fluid dynamics (CFD) simulations performed on ten models of coronary artery diseased subjects and healthy. Specific biochemical mass transportation models developed for the study of low-density lipoprotein, nitric oxide, adenosine triphosphate, oxygen, monocyte chemoattractant protein-1, and transportation monocytes.
Results of transport compared to vector WSS and WSS Lagrangian coherent structures (WSS LCS). WSS high magnitude protected against atherosclerosis by increasing production or biochemical flux atheroprotective and reduce localization near-wall biochemistry atherogenic.
The amount of lower WSS promoted atherosclerosis by increasing localization of biochemical atherogenic. Finally, it’s interesting roles WSS SKB more complex where he was promoted or prevented by different biochemical atherosclerosis. We present a summary of the different pathways by which the WSS affect coronary artery atherosclerosis and compare mechanotransduction and biotransport different mechanisms.
Development of volatile organic compounds and their glycosylated precursors in tamarillo (Solanum betaceum Cav.) During fruit ripening: A prediction of biochemical pathways
key metabolites and pathways flavor-regulation in tamarillo investigated to explore the development of a free and glycosylation of volatile organic compounds (VOCs) during fruit ripening. The concentration of VOC-free and bound was determined by analysis by gas chromatography-mass spectrometry. Changes in physical parameters, the concentration of flavor precursors and key endogenous enzyme activity was also monitored.
A total of 22 VOC-free identified with C6 alcohols and esters into the main compound. Of the 83 VOCs detected glycosylation, phenols and terpenoids are the dominant component. The total concentration of VOCs is bound to increase up to four times during the ripening of fruit. Lipoxygenase pathway is confirmed as an important biosynthetic mechanism for the generation of VOC free and glycosylation during maturation tamarillo. This biosynthetic pathway is highly correlated with the activity of key enzymes and content of the substrate, especially of linolenic acid (p <0.05 or p <0.01).
Phenotypic, genotypic and biochemical changes during the selection of pyrethroid resistance in Anopheles gambiae mosquitoes
Directional Selection for insecticide resistance due to the indiscriminate use of insecticides in public health and agriculture system favors increased frequency of insecticide-resistant alleles in natural populations. Similarly, the removal of the selection pressure generally leads to rot in the resistance. recent investigations on the emergence of insecticide resistance in mosquitoes largely rely on field surveys resistance in vector populations that typically have a complex history of exposure to a variety of public health insecticides and pest control agricultural in nature, and thus the effects of certain insecticides on resistance levels level of emergency or resistance to decay unknown.
This study examined the phenotypic, genotypic, and biochemical changes that occur during the selection process for pyrethroid resistance in Anopheles gambiae, the most important vector of malaria in Africa. In parallel, we also examined the changes in the population hold when there is no selection pressure is applied.
Through repeated deltamethrin selection in adult mosquitoes from field populations collected in western Kenya for 12 generations, we obtain three independent and highly pyrethroid resistant An. gambiae populations. Three vulnerable populations from the same parent population is generated by removing the selection pressure.
Second row mosquito populations differ significantly in monooxygenases and beta-esterase activity, but not in Vgsc frequency of gene mutations, suggesting a metabolic detoxification mechanisms play a major role in generating resistance moderate intensity or high intensity resistance. Pre-exposure synergist piperonyl butoxide restored susceptibility to insecticides among highly resistant mosquitoes, confirming the role of monooxygenases in pyrethroid resistance.
The level of damage resistance to be fully susceptible of moderate intensity resistance took 15 generations, to support at least 2-year interval is required when using the rotation of insecticides with different modes of action to be considered for resistance management.
Biochemical parameters in Cognitive Function
cognitive impairment is a common disease. Many studies tried to elucidate the mechanisms of this dysfunction establishment, including the correlation between cognitive function and biochemical parameters. The scientists are looking for substances that will be an indicator of cognitive function and that can be determined in the cerebrospinal fluid or blood from subjects. Until now, they have isolated several such substances; However, research on the specificity of their validity and the possibility of their use in diagnostic and prognostic assessment is still ongoing.
However, there are only a few reports in the literature systematize the existing knowledge about this, and they are mostly associated with Alzheimer’s disease, not cognition in general, or refer only to certain groups of substances. This article discusses the most important biochemical exponent of cognitive function.
GALNT4 siRNA |
|||
| 20-abx917540 | Abbexa |
|
|
GALNT4 siRNA |
|||
| 20-abx917541 | Abbexa |
|
|
anti-GALNT4 |
|||
| YF-PA15797 | Abfrontier | 50 ul | EUR 435.6 |
|
Description: Mouse polyclonal to GALNT4 |
|||
anti-GALNT4 |
|||
| YF-PA15798 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to GALNT4 |
|||
GALNT4 Blocking Peptide |
|||
| 33R-1400 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GALNT4 antibody, catalog no. 70R-7245 |
|||
GALNT4 Blocking Peptide |
|||
| 33R-9559 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GALNT4 antibody, catalog no. 70R-7248 |
|||
GALNT4 Rabbit pAb |
|||
| A4243-100ul | Abclonal | 100 ul | EUR 369.6 |
GALNT4 Rabbit pAb |
|||
| A4243-200ul | Abclonal | 200 ul | EUR 550.8 |
GALNT4 Rabbit pAb |
|||
| A4243-20ul | Abclonal | 20 ul | Ask for price |
GALNT4 Rabbit pAb |
|||
| A4243-50ul | Abclonal | 50 ul | Ask for price |
GALNT4 Blocking Peptide |
|||
| DF13031-BP | Affbiotech | 1mg | EUR 234 |
GALNT4 cloning plasmid |
|||
| CSB-CL836662HU-10ug | Cusabio | 10ug | EUR 451.2 |
|
Description: A cloning plasmid for the GALNT4 gene. |
|||
Human GALNT4 shRNA Plasmid |
|||
| 20-abx955721 | Abbexa |
|
|
Mouse GALNT4 shRNA Plasmid |
|||
| 20-abx970459 | Abbexa |
|
|
GALNT4 ELISA KIT|Human |
|||
| EF009763 | Lifescience Market | 96 Tests | EUR 826.8 |
Mouse Galnt4 ELISA KIT |
|||
| ELI-27156m | Lifescience Market | 96 Tests | EUR 1038 |
Human GALNT4 ELISA KIT |
|||
| ELI-30796h | Lifescience Market | 96 Tests | EUR 988.8 |
GALNT4 Recombinant Protein (Human) |
|||
| RP012883 | ABM | 100 ug | Ask for price |
GALNT4 Recombinant Protein (Rat) |
|||
| RP202175 | ABM | 100 ug | Ask for price |
GALNT4 Recombinant Protein (Mouse) |
|||
| RP135836 | ABM | 100 ug | Ask for price |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| 20-abx003143 | Abbexa |
|
|
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx122500-100ug | Abbexa | 100 ug | EUR 469.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| 20-abx116519 | Abbexa |
|
|
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx036817-100ug | Abbexa | 100 ug | EUR 469.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx025629-400ul | Abbexa | 400 ul | EUR 627.6 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx025629-80l | Abbexa | 80 µl | EUR 343.2 |
Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) Antibody |
|||
| abx233324-100ug | Abbexa | 100 ug | EUR 610.8 |
Galnt4 ORF Vector (Rat) (pORF) |
|||
| ORF067393 | ABM | 1.0 ug DNA | EUR 607.2 |
GALNT4 ORF Vector (Human) (pORF) |
|||
| ORF004295 | ABM | 1.0 ug DNA | EUR 114 |
Galnt4 ORF Vector (Mouse) (pORF) |
|||
| ORF045280 | ABM | 1.0 ug DNA | EUR 607.2 |
POC1B-GALNT4 Recombinant Protein (Human) |
|||
| RP084084 | ABM | 100 ug | Ask for price |
POC1B-GALNT4 ORF Vector (Human) (pORF) |
|||
| ORF028029 | ABM | 1.0 ug DNA | Ask for price |
Galnt4 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7515601 | ABM | 3 x 1.0 ug | EUR 406.8 |
GALNT4 sgRNA CRISPR Lentivector set (Human) |
|||
| K0835401 | ABM | 3 x 1.0 ug | EUR 406.8 |
Galnt4 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3418201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7515602 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7515603 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7515604 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0835402 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0835403 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0835404 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3418202 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3418203 | ABM | 1.0 ug DNA | EUR 184.8 |
Galnt4 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3418204 | ABM | 1.0 ug DNA | EUR 184.8 |
GALNT4 Protein Vector (Human) (pPB-C-His) |
|||
| PV017177 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Human) (pPB-N-His) |
|||
| PV017178 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Human) (pPM-C-HA) |
|||
| PV017179 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Human) (pPM-C-His) |
|||
| PV017180 | ABM | 500 ng | EUR 394.8 |
GALNT4 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV181118 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV181119 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV181120 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV181121 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPB-C-His) |
|||
| PV269570 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPB-N-His) |
|||
| PV269571 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV269572 | ABM | 500 ng | EUR 723.6 |
GALNT4 Protein Vector (Rat) (pPM-C-His) |
|||
| PV269573 | ABM | 500 ng | EUR 723.6 |
GALNT4 3'UTR Luciferase Stable Cell Line |
|||
| TU008523 | ABM | 1.0 ml | EUR 2799.6 |
Galnt4 3'UTR GFP Stable Cell Line |
|||
| TU254930 | ABM | 1.0 ml | Ask for price |
Galnt4 3'UTR Luciferase Stable Cell Line |
|||
| TU106887 | ABM | 1.0 ml | Ask for price |
GALNT4 3'UTR GFP Stable Cell Line |
|||
| TU058523 | ABM | 1.0 ml | EUR 2799.6 |
Galnt4 3'UTR Luciferase Stable Cell Line |
|||
| TU204930 | ABM | 1.0 ml | Ask for price |
Galnt4 3'UTR GFP Stable Cell Line |
|||
| TU156887 | ABM | 1.0 ml | Ask for price |
Human Polypeptide N-Acetylgalactosaminyltransferase 4 (GALNT4) ELISA Kit |
|||
| abx387484-96tests | Abbexa | 96 tests | EUR 1093.2 |
GALNT4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV638647 | ABM | 1.0 ug DNA | EUR 818.4 |
GALNT4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV638651 | ABM | 1.0 ug DNA | EUR 818.4 |
GALNT4 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV638652 | ABM | 1.0 ug DNA | EUR 818.4 |
POC1B-GALNT4 Protein Vector (Human) (pPB-C-His) |
|||
| PV112114 | ABM | 500 ng | Ask for price |
POC1B-GALNT4 Protein Vector (Human) (pPB-N-His) |
|||
| PV112115 | ABM | 500 ng | Ask for price |
POC1B-GALNT4 Protein Vector (Human) (pPM-C-HA) |
|||
| PV112116 | ABM | 500 ng | Ask for price |
POC1B-GALNT4 Protein Vector (Human) (pPM-C-His) |
|||
| PV112117 | ABM | 500 ng | Ask for price |
POC1B-GALNT4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV741131 | ABM | 1.0 ug DNA | Ask for price |
POC1B-GALNT4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV741135 | ABM | 1.0 ug DNA | Ask for price |
POC1B-GALNT4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV741136 | ABM | 1.0 ug DNA | Ask for price |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K7515605 | ABM | 3 x 1.0 ug | EUR 451.2 |
GALNT4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0835405 | ABM | 3 x 1.0 ug | EUR 451.2 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3418205 | ABM | 3 x 1.0 ug | EUR 451.2 |
GALNT4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV638648 | ABM | 1.0 ug DNA | EUR 818.4 |
GALNT4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV638649 | ABM | 1.0 ug DNA | EUR 888 |
GALNT4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV638650 | ABM | 1.0 ug DNA | EUR 888 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K7515606 | ABM | 1.0 ug DNA | EUR 200.4 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K7515607 | ABM | 1.0 ug DNA | EUR 200.4 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K7515608 | ABM | 1.0 ug DNA | EUR 200.4 |
GALNT4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0835406 | ABM | 1.0 ug DNA | EUR 200.4 |
GALNT4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0835407 | ABM | 1.0 ug DNA | EUR 200.4 |
GALNT4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0835408 | ABM | 1.0 ug DNA | EUR 200.4 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3418206 | ABM | 1.0 ug DNA | EUR 200.4 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3418207 | ABM | 1.0 ug DNA | EUR 200.4 |
Galnt4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3418208 | ABM | 1.0 ug DNA | EUR 200.4 |
POC1B-GALNT4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV741132 | ABM | 1.0 ug DNA | Ask for price |
POC1B-GALNT4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV741133 | ABM | 1.0 ug DNA | Ask for price |
POC1B-GALNT4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV741134 | ABM | 1.0 ug DNA | Ask for price |
Positive control tissue section for each individua |
|||
| Control-Slides-for-each-antibody | Innovex | Set of 25 | EUR 355 |
|
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE |
|||
CD11b Antibody Antibody |
|||
| ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
ASAP1 antibody Antibody |
|||
| DF8746 | Affbiotech | 200ul | EUR 420 |
anti- Antibody^Polyclonal antibody control antibody |
|||
| LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
| A1360-500 | Biovision | each | Ask for price |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| 20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx008109 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx123734 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319913 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx324434 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx311665 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
Anti-Anti-SEPT6 antibody antibody |
|||
| STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
|||
Anti-Anti-SEPT9 Antibody antibody |
|||
| STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
|||
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
| STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
|||
Anti-Anti-MARCH9 Antibody antibody |
|||
| STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-MARCH8 Antibody antibody |
|||
| STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT12 Antibody antibody |
|||
| STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
| STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
| STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT1 antibody antibody |
|||
| STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
|||
CLCN5 Antibody / CIC-5 antibody |
|||
| RQ6462 | NSJ Bioreagents | 100ug | EUR 419 |
|
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
|||
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-100ul | SAB | 100ul | EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-50ul | SAB | 50ul | EUR 286.8 |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: anti-CD22 monoclonal antibody |
|||
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: anti-CD22 monoclonal antibody |
|||
Antibody Pair to ApoA-V antibody |
|||
| 10R-1876 | Fitzgerald | 100 ul | EUR 781.2 |
|
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
|||
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
| abx023924-1mg | Abbexa | 1 mg | EUR 1446 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319929 | Abbexa |
|
|